CytomX Therapeutics Inc
Research CytomX Therapeutics Inc (CTMX) on Bullrun: market cap USD 734.32M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCTMX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 734.32M
- Financial periodQ2 2026
- RevenueUSD 1.42M
- Net income-USD 20.67M
- Free cash flow-USD 18.07M
Valuation Snapshot
latest market cap is USD 734.32M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 76.20M | -USD 17.37M | -USD 75.81M | n/a | 0.03 | USD 12.67M | USD 4.24M | USD 99.01M |
| FY2024 | USD 138.10M | USD 31.87M | -USD 86.54M | n/a | n/a | USD 38.05M | USD 9.39M | -USD 456.00K |
| FY2023 | USD 101.21M | -USD 569.00K | -USD 56.88M | n/a | -0.04 | USD 17.17M | USD 13.97M | -USD 47.45M |
| FY2022 | USD 53.16M | -USD 99.32M | -USD 112.53M | n/a | n/a | USD 193.65M | USD 19.92M | -USD 85.75M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 734.32M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 724.99M | 426.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 82.50M | 2.6 | n/a | n/a |
| 2023 | 2023-12-29 | USD 103.83M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 105.74M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 283.15M | n/a | n/a | n/a |
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CytomX Therapeutics Inc's market cap?
CytomX Therapeutics Inc's market capitalization is USD 734.32M.
What does CytomX Therapeutics Inc do?
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.